306 related articles for article (PubMed ID: 17630052)
1. The outbreak of meningitis due to Neisseria meningitidis W135 in 2003 in Burkina Faso and the national response: main lessons learnt.
Zombré S; Hacen MM; Ouango G; Sanou S; Adamou Y; Koumaré B; Kondé MK
Vaccine; 2007 Sep; 25 Suppl 1():A69-71. PubMed ID: 17630052
[TBL] [Abstract][Full Text] [Related]
2. Chronicle of an outbreak foretold: meningococcal meningitis W135 in Burkina Faso.
Decosas J; Koama JB
Lancet Infect Dis; 2002 Dec; 2(12):763-5. PubMed ID: 12467693
[TBL] [Abstract][Full Text] [Related]
3. The rise and fall of epidemic Neisseria meningitidis serogroup W135 meningitis in Burkina Faso, 2002-2005.
Traoré Y; Njanpop-Lafourcade BM; Adjogble KL; Lourd M; Yaro S; Nacro B; Drabo A; Parent du Châtelet I; Mueller JE; Taha MK; Borrow R; Nicolas P; Alonso JM; Gessner BD
Clin Infect Dis; 2006 Oct; 43(7):817-22. PubMed ID: 16941360
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of a trivalent serogroup A/C/W135 meningococcal polysaccharide vaccine in Burkina Faso, 2003.
Soriano-Gabarró M; Toé L; Tiendrebeogo SR; Nelson CB; Dabal M; Djingarey MH; Plikaytis B; Rosenstein N;
Vaccine; 2007 Sep; 25 Suppl 1():A92-6. PubMed ID: 17517451
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Pastorex meningitis kit for the rapid identification of Neisseria meningitidis serogroups A and W135.
Djibo S; Njanpop Lafourcade BM; Boisier P; Moussa A; Kobo G; Sidikou F; Hien A; Bieboure G; Aguilera JF; Parent du Chatelet I; Gessner BD; Chanteau S
Trans R Soc Trop Med Hyg; 2006 Jun; 100(6):573-8. PubMed ID: 16406096
[TBL] [Abstract][Full Text] [Related]
6. Meningococcal serogroup W135 in the African meningitis belt: epidemiology, immunity and vaccines.
Mueller JE; Borrow R; Gessner BD
Expert Rev Vaccines; 2006 Jun; 5(3):319-36. PubMed ID: 16827617
[TBL] [Abstract][Full Text] [Related]
7. Preparedness for infectious threats: public-private partnership to develop an affordable vaccine for an emergent threat: the trivalent Neisseria meningitidis ACW135 polysaccharide vaccine.
Nelson CB; Birmingham M; Costa A; Daviaud J; Perea W; Kieny MP; Tarantola D
Am J Public Health; 2007 Apr; 97 Suppl 1(Suppl 1):S15-22. PubMed ID: 17413077
[TBL] [Abstract][Full Text] [Related]
8. The first large epidemic of meningococcal disease caused by serogroup W135, Burkina Faso, 2002.
Koumaré B; Ouedraogo-Traoré R; Sanou I; Yada AA; Sow I; Lusamba PS; Traoré E; Dabal M; Santamaria M; Hacen MM; Kaboré AB; Caugant DA
Vaccine; 2007 Sep; 25 Suppl 1():A37-41. PubMed ID: 17521783
[TBL] [Abstract][Full Text] [Related]
9. [Clonal expansion of Neisseria meningitidis W135. Epidemiological implications for the African meningitis belt].
du Châtelet IP; Alonso JM; Taha MK
Bull Soc Pathol Exot; 2002 Dec; 95(5):323-4; discussion 324-5. PubMed ID: 12696368
[TBL] [Abstract][Full Text] [Related]
10. Infectious disease. Shortage of meningitis vaccine forces triage in Burkina Faso.
Vogel G
Science; 2003 Mar; 299(5612):1499-501. PubMed ID: 12624241
[No Abstract] [Full Text] [Related]
11. Meningitis serogroup W135 outbreak, Burkina Faso, 2002.
Nathan N; Rose AM; Legros D; Tiendrebeogo SR; Bachy C; Bjørløw E; Firmenich P; Guerin PJ; Caugant DA
Emerg Infect Dis; 2007 Jun; 13(6):920-3. PubMed ID: 17553237
[TBL] [Abstract][Full Text] [Related]
12. Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience.
Djingarey MH; Barry R; Bonkoungou M; Tiendrebeogo S; Sebgo R; Kandolo D; Lingani C; Preziosi MP; Zuber PL; Perea W; Hugonnet S; Dellepiane de Rey Tolve N; Tevi-Benissan C; Clark TA; Mayer LW; Novak R; Messonier NE; Berlier M; Toboe D; Nshimirimana D; Mihigo R; Aguado T; Diomandé F; Kristiansen PA; Caugant DA; Laforce FM
Vaccine; 2012 May; 30 Suppl 2():B40-5. PubMed ID: 22607898
[TBL] [Abstract][Full Text] [Related]
13. Epidemiological patterns of meningococcal meningitis in Niger in 2003 and 2004: under the threat of N. meningitidis serogroup W135.
Boisier P; Djibo S; Sidikou F; Mindadou H; Kairo KK; Djibo A; Goumbi K; Chanteau S
Trop Med Int Health; 2005 May; 10(5):435-43. PubMed ID: 15860090
[TBL] [Abstract][Full Text] [Related]
14. [First major epidemic caused by Neisseria meningitidis serogroup W135 in Africa?].
Bertherat E; Yada A; Djingarey MH; Koumare B
Med Trop (Mars); 2002; 62(3):301-4. PubMed ID: 12322694
[TBL] [Abstract][Full Text] [Related]
15. Emergence of W135 meningococcal meningitis in Ghana.
Forgor AA; Leimkugel J; Hodgson A; Bugri A; Dangy JP; Gagneux S; Smith T; Pluschke G
Trop Med Int Health; 2005 Dec; 10(12):1229-34. PubMed ID: 16359402
[TBL] [Abstract][Full Text] [Related]
16. Serogroup A meningococcal conjugate vaccine coverage after the first national mass immunization campaign-Burkina Faso, 2011.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2012 Dec; 61(50):1022-4. PubMed ID: 23254256
[TBL] [Abstract][Full Text] [Related]
17. Monitoring of adverse events during the 2003 mass vaccination campaign with a trivalent meningococcal A/C/W135 polysaccharide vaccine in Burkina Faso.
Bentsi-Enchill AD; Zongo I; Khamassi S; Pless R; Thombiano R; Tiéndrebéogo S; Nelson CB; Duclos P
Vaccine; 2007 Sep; 25 Suppl 1():A72-8. PubMed ID: 17544552
[TBL] [Abstract][Full Text] [Related]
18. Bacterial meningitis in Burkina Faso: surveillance using field-based polymerase chain reaction testing.
Parent du Châtelet I; Traore Y; Gessner BD; Antignac A; Naccro B; Njanpop-Lafourcade BM; Ouedraogo MS; Tiendrebeogo SR; Varon E; Taha MK
Clin Infect Dis; 2005 Jan; 40(1):17-25. PubMed ID: 15614687
[TBL] [Abstract][Full Text] [Related]
19. Meningococcal carriage and immunity in western Burkina Faso, 2003.
Yaro S; Traoré Y; Tarnagda Z; Sangaré L; NjanpopLafourcade BM; Drabo A; Findlow H; Borrow R; Nicolas P; Gessner BD; Mueller JE
Vaccine; 2007 Sep; 25 Suppl 1():A42-6. PubMed ID: 17559988
[TBL] [Abstract][Full Text] [Related]
20. Meningitis epidemics in Africa: a brief overview.
Teyssou R; Muros-Le Rouzic E
Vaccine; 2007 Sep; 25 Suppl 1():A3-7. PubMed ID: 17643560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
